Gain Therapeutics, Inc. Common Stock GANX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-06T20:54:24.292Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T20:54:05.668804842Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-06T20:50:58.666567+00:00
Gain Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 0.82 | 728.6% | 67.9% | |||
| 25Δ | 1.00 | 688.9% | 50.0% | |||
| 30Δ | 1.08 | 640.2% | 44.7% | |||
| 35Δ | 1.15 | 591.4% | 39.4% | |||
| 40Δ | 1.23 | 542.7% | 34.1% | |||
| 45Δ | 1.30 | 494.0% | 28.8% | |||
| 50Δ | 1.38 | 445.2% | 23.5% | |||
| 55Δ | 1.45 | 396.5% | 18.2% | |||
| 60Δ | 1.54 | 361.7% | 14.1% | |||
| 65Δ | 1.66 | 348.8% | 11.8% | |||
| 70Δ | 1.78 | 335.9% | 9.5% | |||
| 75Δ | 0.87 | 600.6% | 34.8% | 1.89 | 322.9% | 7.2% |
| 80Δ | 0.74 | 666.5% | 29.4% | 2.09 | 319.8% | 5.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.82
- IV
- 728.6%
- B/E move
- 67.9%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.00
- IV
- 688.9%
- B/E move
- 50.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.08
- IV
- 640.2%
- B/E move
- 44.7%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.15
- IV
- 591.4%
- B/E move
- 39.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.23
- IV
- 542.7%
- B/E move
- 34.1%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.30
- IV
- 494.0%
- B/E move
- 28.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.38
- IV
- 445.2%
- B/E move
- 23.5%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.45
- IV
- 396.5%
- B/E move
- 18.2%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.54
- IV
- 361.7%
- B/E move
- 14.1%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.66
- IV
- 348.8%
- B/E move
- 11.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.78
- IV
- 335.9%
- B/E move
- 9.5%
75Δ
- Pseudo strike
- 0.87
- IV
- 600.6%
- B/E move
- 34.8%
- Pseudo strike
- 1.89
- IV
- 322.9%
- B/E move
- 7.2%
80Δ
- Pseudo strike
- 0.74
- IV
- 666.5%
- B/E move
- 29.4%
- Pseudo strike
- 2.09
- IV
- 319.8%
- B/E move
- 5.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 282.62% | |
| 234.70% | |
| 274.40% | |
| 299.20% | |
| 196.99% | |
| 188.48% | |
| 214.53% | |
| 213.81% | |
| 187.28% | |
| 199.30% | |
| 228.48% | |
| 296.02% | |
| 232.36% | |
| 272.03% | |
| 235.65% |
Biotechnology
GENB
Generate Biomedicines, Inc. is an innovative biotechnology company at the forefront of protein therapeutics development, leveraging advanced genetic engineering and artificial…
More →GERN
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The…
More →GHRS
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The…
More →GLUE
Description unavailable
More →GMAB
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
More →GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive…
More →